Dr. Reddy's Laboratories Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Erez Israeli

Algemeen directeur

₹230.3m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	4.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Erez Israeli's beloning veranderd ten opzichte van Dr. Reddy's Laboratories's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2026	₹230m	n/a	₹43b
Dec 31 2025	n/a	n/a	₹57b
Sep 30 2025	n/a	n/a	₹59b
Jun 30 2025	n/a	n/a	₹57b
Mar 31 2025	₹175m	n/a	₹57b
Dec 31 2024	n/a	n/a	₹54b
Sep 30 2024	n/a	n/a	₹53b
Jun 30 2024	n/a	n/a	₹56b
Mar 31 2024	₹197m	n/a	₹56b
Dec 31 2023	n/a	n/a	₹52b
Sep 30 2023	n/a	n/a	₹51b
Jun 30 2023	n/a	n/a	₹47b
Mar 31 2023	₹195m	n/a	₹45b
Dec 31 2022	n/a	n/a	₹36b
Sep 30 2022	n/a	n/a	₹31b
Jun 30 2022	n/a	n/a	₹30b
Mar 31 2022	₹127m	n/a	₹24b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹19b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹120m	n/a	₹17b
Dec 31 2020	n/a	n/a	₹21b
Sep 30 2020	n/a	n/a	₹15b
Jun 30 2020	n/a	n/a	₹19b
Mar 31 2020	₹195m	₹107m	₹19b

Compensatie versus markt: De totale vergoeding ($USD 2.41M ) Erez } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 6.03M ).

Compensatie versus inkomsten: De beloning van Erez is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Erez Israeli (58 yo)

8.3yrs

Tenure

₹230,330,000

Compensatie

Mr. Erez Israeli, MBA has been Chief Executive Officer of Dr. Reddy's Laboratories Limited since August 1, 2019 and has been its Member of the Management Council since April 02, 2018. Mr. Israeli served as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gunupati Prasad	Co-Chairman	40.3yrs	₹158.17m	13.08% € 1.3b
Kallam Reddy	Chairman of the Board & Member of the Management Council	33.5yrs	₹100.66m	13.62% € 1.4b
Erez Israeli	CEO & Member of the Management Council	8.3yrs	₹230.33m	geen gegevens
Mannam Venkatanarasimham	CFO & Member of the Management Council	1.9yrs	₹72.48m	0.0074% € 756.8k
Krishna Venkatesh	Global Head of IPDO	2.5yrs	₹41.18m	geen gegevens
Deepak Sapra	Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council	no data	₹50.89m	0.0091% € 933.7k
Motupalli Ramana	CEO of Global Generics & Member of Management Council	no data	₹89.25m	0.0082% € 842.2k
Sanjay Sharma	Executive VP	8.9yrs	₹71.07m	geen gegevens
Patrick Aghanian	Head of Consumer Health Organization & Member of Management Council	no data	₹107.54m	0.0010% € 103.9k
Bhethanabottla Phanimitra	Chief Digital & Information Officer and Member of the Management Council	2.9yrs	₹37.54m	0.0010% € 108.0k
Milan Kalawadia	CEO of North America & Member of Management Council	2.2yrs	₹86.78m	0.0057% € 584.1k
M S Sundar	Global Head of Quality and PV & Member of Management Council	less than a year	geen gegevens	0.0043% € 440.1k

2.5yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RDDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gunupati Prasad	Co-Chairman	40.3yrs	₹158.17m	13.08% € 1.3b
Kallam Reddy	Chairman of the Board & Member of the Management Council	33.5yrs	₹100.66m	13.62% € 1.4b
Claudio Albrecht	Independent Director	3.2yrs	₹20.24m	geen gegevens
Arun Kumar	Independent Director	3.9yrs	₹22.14m	geen gegevens
Shikha Sharma	Independent Director	7.5yrs	₹16.45m	geen gegevens
Leo Puri	Lead Independent Director	7.8yrs	₹22.62m	geen gegevens
Kodumudi Krishnan	Independent Director	4.5yrs	₹14.18m	geen gegevens
Sanjiv Mehta	Independent Director	2.6yrs	₹17.40m	geen gegevens
Alpna Seth	Independent Director	3.5yrs	₹19.77m	geen gegevens
Penny Wan	Independent Director	4.5yrs	₹20.72m	geen gegevens

4.5yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RDDA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/07/08 05:28
Aandelenkoers aan het einde van de dag	2026/07/08 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2026/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Dr. Reddy's Laboratories Limited wordt gevolgd door 70 analisten. 36 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Rohit Bhat	360 ONE Capital Market Private Limited
Gaurav Tinani	Ambit Capital
null null	Anand Rathi Shares and Stock Brokers Limited

Dr. Reddy's Laboratories Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 24, 2025

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Recent updates

Dr. Reddy's Laboratories Limited to Report Q1, 2027 Results on Jul 22, 2026

Dr. Reddy’s Laboratories Announces First-To-Market Launch Of Bosutinib Tablets 400Mg, A Generic Equivalent Of Bosulif, In The United States

Dr. Reddy’S Laboratories Ltd. Launches Generic Semaglutide Injection in Canada

Dr. Reddy's Laboratories Limited announces Annual dividend, payable on August 22, 2026

Dr Reddys Laboratories Ltd Receives Health Canada Approval For Generic Semaglutide Injection

Enspirit Technology Services Private Limited entered into an agreement to acquire Svaas Wellness Limited from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 22.3 million.

CORONA Remedies Limited (NSEI:CORONA) acquired Wokadine Brand from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Limited to Report Q4, 2026 Results on May 12, 2026

Dr. Reddy's Announces USFDA Acceptance to Review its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Dr. Reddy's Laboratories Ltd. Announces the Launch of Over-The-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%

Dr. Reddy's Laboratories Limited to Report Q3, 2026 Results on Jan 21, 2026

USFDA Inspection Closes with Voluntary Action Indicated Classification

Eisai Co., Ltd. Announces Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for AVT03 (denosumab), A Proposed Biosimilar of Prolia®? and Xgeva®?

Dr. Reddy's Laboratories Limited to Report Q2, 2026 Results on Oct 24, 2025

Extrovis AG and Dr. Reddy's Announce the Launch of the Authorized Generic of Carac (Fluorouracil Cream), 0.5% in the U.S

Dr. Reddy's Laboratories Limited to Report Q1, 2026 Results on Jul 23, 2025

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 24, 2025

Dr. Reddy's Laboratories Limited Recommends A Final Dividend for the Financial Year 2024-25

Dr. Reddy's Laboratories Limited to Report Q4, 2025 Results on May 09, 2025

Dr. Reddy's Issues Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 Mg/100 mL, in the U.S., Due to Mislabeling of Infusion Bag

Senores Pharmaceuticals, Inc. agreed to acquire basket of 14 Abbreviated New Drug Applications from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Provides Lawsuit Updates

Dr. Reddy's Laboratories Limited to Report Q3, 2025 Results on Jan 23, 2025

Dr. Reddy's Laboratories Ltd. Launches Toripalimab in India

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Complaint Made Public in the United States District Court for the District of New Jersey

Dr. Reddy's Laboratories Limited to Report Q2, 2025 Results on Nov 05, 2024

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Fiscal Year 2024

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.